Ceribell

Ceribell Forward P/E

The Forward P/E Ratio of Ceribell (CBLL) as of Nov 4, 2026 is -13.09. In the previous year, Forward P/E Ratio was -17.28 — a change of -24.26% (higher).

Forward P/E

-13.09

YoY

-24.26%

Last updated:

Forward P/E Ratio of Ceribell is 2025 -13.09 . Forward P/E Ratio of Ceribell was 2024 -17.28 . It decreases by -24.26% higher compared to the previous year.

The Ceribell Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2022
-18.81 USD
Jan 1, 2023
-23.72 USD
Jan 1, 2024
-17.28 USD
Jan 1, 2025
-13.09 USD
The Ceribell Forward P/E history
YEARForward P/EYoY
-13.09-24.26%
-17.28-27.17%
-23.72+26.13%
-18.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ceribell Stock analysis

What does Ceribell do? Ceribell, Inc. generates revenue through its Ceribell System, a point-of-care EEG platform designed for acute care settings. The system combines portable hardware with AI-powered algorithms, including the Clarity AI algorithm that provides real-time EEG interpretation, bedside alerts, and continuous monitoring for status epilepticus. Hospitals and healthcare providers purchase the Ceribell System to improve neurological diagnosis and management, particularly for patients with acute conditions requiring rapid seizure detection. The Ceribell EEG Portal is also offered as part of the solution to facilitate data access and management. The company's primary customers are healthcare institutions seeking to enhance patient care efficiency through advanced neurological monitoring. By enabling early detection and continuous monitoring, the Ceribell System supports precise treatment decisions and reduces hospital resource strain. The Clarity AI algorithm is a key differentiator, delivering real-time insights that address critical unmet needs in acute neurological care. Ceribell, Inc. focuses on transforming diagnosis and management of serious neurological conditions through its proprietary technology. The Ceribell System's portability and rapid deployment make it suitable for acute care environments where timely intervention is crucial. Healthcare providers use the system to monitor patients with suspected seizures, leveraging the AI-driven insights for immediate clinical action. Ceribell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ceribell stock

Forward P/E Ratio of Ceribell is -13.09 in 2025.

Forward P/E Ratio of Ceribell changed from -17.28 to -13.09, representing a -24.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Ceribell since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Ceribell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Ceribell

All Key Metrics — Ceribell